AstraZeneca (NASDAQ:AZN) stock received a positive assessment from UBS, as analyst Matthew Weston upgraded the pharmaceutical giant's rating from Neutral to Buy. The upgrade was accompanied by a ...

AstraZeneca PLC (LON:AZN:LN) (NASDAQ: AZN), a pharmaceutical giant with a market capitalization of $224.5 billion, received a new Overweight rating from Morgan Stanley (NYSE:MS), accompanied by a ...

AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the ...

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

In a report released today, Matthew Weston from UBS upgraded AstraZeneca (AZN – Research Report) to a Buy, with a price target of £142.00. The ...

Shares in drugs giant AstraZeneca (AZN) looked perkier today as it reported a rise in sales and eased investor fears over the ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

Today, Benzinga's options scanner spotted 9 options trades for AstraZeneca. This isn't normal. The overall sentiment of these ...

Employing factors like one-week price change and the monthly percentage ... Momentum investors should take note of this Medical stock. AZN has a Momentum Style Score of B, and shares are up ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AstraZeneca's improving financial position isn't yet fully reflected in its stock price AstraZeneca's revenue was about $13.57 billion in the third quarter of 2024, up 18.1% year-over-year and 4. ...